

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/35920 A1(51) International Patent Classification⁷: A61K 7/48

(21) International Application Number: PCT/GB00/04304

(22) International Filing Date:
9 November 2000 (09.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/165,830 16 November 1999 (16.11.1999) US

(71) Applicant (for AE, AG, AU, BB, BZ, CA, CY, DM, GB, GD, GH, GM, IE, IL, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW only): UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).

(71) Applicant (for all designated States except AE, AG, AU, BB, BZ, CA, CY, DM, GB, GD, GH, GM, IE, IL, IN, KE, LC, LK, LS, MN, MW, NZ, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZW): UNILEVER NV [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).

(71) Applicant (for IN only): HINDUSTAN LEVER LIMITED [IN/IN]; Hindustan Lever House, 165/166 Backbay Reclamation, Mumbai 400 020 (IN).

(72) Inventors: PILLAI, Sreekumar; Unilever Research U.S. Inc., 45 River Road, Edgewater, NJ 07020 (US).

GRANGER, Stewart, Paton; Unilever Research U.S. Inc., 45 River Road, Edgewater, NJ 07020 (US). POCALEJKO, David, Joseph; Unilever Research U.S. Inc., 45 River Road, Edgewater, NJ 07020 (US). MAHAJAN, Manisha, Narayan; Unilever Research U.S. Inc., 45 River Road, Edgewater, NJ 07020 (US).

(74) Agent: BAKER, Colin, J.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/35920 A1

(54) Title: COSMETIC COMPOSITIONS CONTAINING CHICK PEA EXTRACT AND RETINOID

(57) Abstract: The present invention discloses cosmetic skin care compositions containing chick pea extract in combination with retinoids. Methods of conditioning skin by the application of such compositions to the skin are also disclosed.

- 1 -

COSMETIC COMPOSITIONS CONTAINING
CHICK PEA EXTRACT AND RETINOID

5

FIELD OF THE INVENTION

The present invention relates to cosmetic compositions containing chick pea extract in combination with retinoids and to methods of conditioning skin by the application of 10 such compositions to the skin.

BACKGROUND OF THE INVENTION

Retinol (vitamin A) is an endogenous compound which occurs 15 naturally in the human body and is essential for normal epithelial cell differentiation. Natural and synthetic vitamin A derivatives have been used extensively in the treatment of a variety of skin disorders and as skin repair and renewal agents. Retinoic acid has been used to treat a 20 variety of skin conditions such as acne, wrinkles, psoriasis, age spots and skin discoloration.

Within the cells, retinol and retinoic acid are bound to 25 specific cellular binding proteins, two of the major proteins are CRABP-1 and -2 (Roos et al., Pharmacological reviews: 50, 315-333, 1998). These proteins act in regulating the intracellular concentration of retinoids by 30 acting as both storage or shuttle proteins in retinoid metabolism. The levels of this protein are regulated by the amount of retinoic acid within the cells. Higher cellular

- 2 -

levels of retinoids increase the expression of CRABP-2. Therefore, the amount of this protein in the cells, is a measure of the retinoid activity of the cells. Skin cells contain CRABP-2 both in the epidermis and the dermis.

5 CRABP-2 response to retinoid administration in fibroblasts *in vitro* is used as a reproducible measure of retinoid bioactivity that predict human skin responses (Elder et al., J. Invest. Dermatol., 106: 517-521, 1996). Therefore, CRABP-2 expression of fibroblasts is a measure of retinoid

10 activity leading to various cosmetic skin benefits (antiaging, anti wrinkling, skin conditioning etc.).

Chick pea or Spanish pea (*Cicer arietinum*), a common dietary lentil, contains flavonoids including daidzein, formononetin, biochanin A, pratensein, homoferreirin, medicarpin, maackiain, methyl coumestrol, medicagol, formononetin glucoside and biochanin A glucoside (Ingham et al., In: Progress in the chemistry of Organic natural products, vol 43: Ed-W. Herz et al., Springer-Verlag, Wien, 20 New York, 1983). Flavonoids derived from chick pea have been reported to have lipid lowering effects in the blood and liver of rats. Several nutritional studies report on protein derived from chick pea for use as nutritional supplements and ways to improve the protein quality of chick 25 pea. Vasiliou, US patent 4,761,285 discloses the use of chick peas as a dietary supplement or for internal or topical treatment of haemorrhoids. In India, a cosmetic mask or skin treatment made from chick pea powder mixed with water is a common beauty treatment.

- 3 -

The present invention is based in part on the discovery that the organic solvent chick pea extract in combination with retinoids enhances CRABP-2 expression in fibroblasts.

5

SUMMARY OF THE INVENTION

The present invention relates to a cosmetic skin care composition comprising:

10 (i) an organic solvent extract of chick pea in an amount of from 0.00001 to 10 wt. %;
(ii) a retinoid in an amount of from 0.001 to 10 wt.%; and
(iii) a cosmetically acceptable vehicle.

15 The present invention also includes a method of improving or preventing the condition of wrinkled, lined, dry, flaky, aged or photodamaged skin and improving skin thickness, elasticity, flexibility, radiance, glow and plumpness, which method includes applying the inventive
20 composition to the skin. Compositions of the invention are intended for topical application to mammalian skin which is already dry, flaky, lined, wrinkled, aged, photodamaged, or may be applied prophylactically to reduce the deteriorative changes.

25

DETAILED DESCRIPTION OF THE INVENTION

Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts
30 of material or conditions of reaction, physical properties of materials and/or use are to be understood as modified by the

- 4 -

word "about." All amounts are by weight of the composition, unless otherwise specified.

Chick peas are suitable for use in the inventive
5 compositions in the form of an organic extract. The chick pea extract is prepared for use in the present invention from dried chick peas. Dried chick peas may be obtained from Arrowhead Mills, from health food stores or supermarkets.

10

The organic chick pea extracts are prepared by extracting the dried chick peas with a solvent by stirring 1 part of dried chick peas with 2 to 5 parts of the solvent for from 4 to 24 hours at room temperature. Suitable solvents are described
15 below. The extracts are clarified by filtration and/or centrifugation, then dried by evaporation (optionally, under vacuum) to obtain the organic chick pea extract.

Solvents suitable for the preparation of chick pea extract
20 for use in the present invention include, but are not limited to: ethanol, methanol, hexane, chloroform, dichloromethane and ethyl acetate. Preferred solvents are dichloromethane, methanol, or ethanol in order to optimize activity. The extract may be further concentrated, fractionated, re-extracted
25 or purified, e.g. by organic solvent extraction or by chromatography.

In general, the amount of the chick pea extract in the inventive compositions is in the range of from 0.00001% to
30 10% by weight composition. Preferably in order to lower cost and maximize the effect, the amount of chick pea

- 5 -

extract is in the range of from 0.01 to 10% and most preferably is in the range of from 0.1% to 5% by wt. of the composition.

- 5 The inventive compositions further comprise a retinoid selected from retinol or retinyl ester. The term "retinol" includes the following isomers of retinol: all-trans-retinol, 13-cis-retinol, 11-cis-retinol, 9-cis-retinol, 3,4-didehydro-retinol. Preferred isomers are all-trans-retinol,
- 10 13-cis-retinol, 3,4-didehydro-retinol, 9-cis-retinol. Most preferred is all-trans-retinol, due to its wide commercial availability.

Retinyl ester is an ester of retinol. The term "retinol" has

- 15 been defined above. Retinyl esters suitable for use in the present invention are C₁-C₃₀ esters of retinol, preferably C₂-C₂₀ esters, and most preferably C₂, C₃, and C₁₆ esters because they are more commonly available. Examples of retinyl esters include but are not limited to: retinyl
- 20 palmitate, retinyl formate, retinyl acetate, retinyl propionate, retinyl butyrate, retinyl valerate, retinyl isovalerate, retinyl hexanoate, retinyl heptanoate, retinyl octanoate, retinyl nonanoate, retinyl decanoate, retinyl undecanoate, retinyl laurate, retinyl tridecanoate, retinyl
- 25 myristate, retinyl pentadecanoate, retinyl heptadecanoate, retinyl stearate, retinyl isostearate, retinyl nonadecanoate, retinyl arachidonate, retinyl behenate, retinyl linoleate, retinyl oleate.

30 The preferred ester for use in the present invention is selected from retinyl palmitate, retinyl acetate and retinyl

- 6 -

propionate, because these are the most commercially available and therefore the cheapest. Retinyl linoleate is also preferred due to its efficacy.

5 Retinol or retinyl ester is employed in the inventive composition in an amount of from about 0.001% to about 10%, preferably in an amount of from about 0.01% to about 1%, most preferably in an amount of from about 0.01% to about 0.5% by wt. of the composition.

10 The composition also comprises a cosmetically acceptable vehicle to act as a diluant, dispersant or carrier for the chick pea extract and the retinoid in the composition, so as to facilitate their distribution when the composition is 15 applied to the skin.

Vehicles other than, or in addition to, water can include liquid or solid emollients, solvents, humectants, thickeners and powders. An especially preferred nonaqueous carrier is 20 a polydimethyl siloxane and/or a polydimethyl phenyl siloxane. Silicones of this invention may be those with viscosities ranging anywhere from about 10 to 10,000,000mm²/s (centistokes) at 25°C. Especially desirable are mixtures of low and high viscosity silicones. 25 These silicones are available from the General Electric Company under trademarks Vicasil, SE and SF and from the Dow Corning Company under the 200 and 550 Series. Amounts of silicone which can be utilized in the compositions of this invention range anywhere from 5% to 95%, preferably from 25% 30 to 90% by weight of the composition.

- 7 -

The cosmetically acceptable vehicle will usually comprise from 5% to 99.9%, preferably from 25% to 80% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition. Preferably, 5 the vehicle is at least 80 wt.% water, by weight of the vehicle. Preferably, water comprises at least 50 wt.% of the inventive composition, most preferably from 60 to 80 wt.%, by weight of the composition.

10 Optional Skin Benefit Materials and Cosmetic Adjuncts

An oil or oily material may be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average 15 hydrophilic-lipophilic balance (HLB) of the emulsifier employed.

The compositions of the present invention preferably include sunscreens. Sunscreens include those materials commonly 20 employed to block ultraviolet light. Illustrative compounds are the derivatives of PABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are 25 commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively. The exact amount of sunscreen employed in the emulsions may vary depending upon the degree of protection desired from the sun's UV radiation.

30 Emollients may also be incorporated into cosmetic compositions of the present invention. Levels of such

- 8 -

emollients may range from 0.5% to 50%, preferably between 5% and 30% by weight of the total composition. Emollients may be classified under such general chemical categories as esters, fatty acids and alcohols, polyols and hydrocarbons.

5

Esters may be mono- or di-esters. Acceptable examples of fatty di-esters include dibutyl adipate, diethyl sebacate, diisopropyl dimerate, and dioctyl succinate. Acceptable branched chain fatty esters include 2-ethyl-hexyl myristate, 10 isopropyl stearate and isostearyl palmitate. Acceptable tribasic acid esters include triisopropyl trilinoleate and trilauryl citrate. Acceptable straight chain fatty esters include lauryl palmitate, myristyl lactate, and stearyl oleate. Preferred esters include coco-caprylate/caprate (a 15 blend of coco-caprylate and coco-caprate), propylene glycol myristyl ether acetate, diisopropyl adipate and cetyl octanoate.

Suitable fatty alcohols and acids include those compounds 20 having from 10 to 20 carbon atoms. Especially preferred are compounds such as cetyl, myristyl, palmitic and stearyl alcohols and acids.

Among the polyols which may serve as emollients are linear 25 and branched chain alkyl polyhydroxyl compounds. For example, propylene glycol, sorbitol and glycerin are preferred. Also useful may be polymeric polyols such as poly-propylene glycol and polyethylene glycol. Butylene and propylene glycol are also especially preferred as 30 penetration enhancers.

- 9 -

Exemplary hydrocarbons which may serve as emollients are those having hydrocarbon chains ranging anywhere from 12 to 30 carbon atoms. Specific examples include mineral oil, petroleum jelly, squalene and isoparaffins.

5

Another category of functional ingredients within the cosmetic compositions of the present invention are thickeners. A thickener will usually be present in amounts anywhere from 0.1 to 20% by weight, preferably from about 10 0.5% to 10% by weight of the composition. Exemplary thickeners are cross-linked polyacrylate materials available under the trademark Carbopol from the B.F. Goodrich Company. Gums may be employed such as xanthan, carrageenan, gelatin, karaya, pectin and locust beans gum. Under certain 15 circumstances the thickening function may be accomplished by a material also serving as a silicone or emollient. For instance, silicone gums in excess of 10 centistokes and esters such as glycerol stearate have dual functionality.

20 Powders may be incorporated into the cosmetic compositions of the present invention. These powders include chalk, talc, kaolin, starch, smectite clays, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed 25 silica, aluminum starch octenyl succinate and mixtures thereof.

Other adjunct minor components may also be incorporated into the cosmetic compositions. These ingredients may include 30 coloring agents, opacifiers and perfumes. Amounts of these

- 10 -

other adjunct minor components may range anywhere from 0.001% up to 20% by weight of the composition.

Use of the Composition

5

The composition according to the invention is intended primarily as a product for topical cosmetic application to human skin, especially as an agent for conditioning, moisturizing and smoothening the skin, and preventing or 10 reducing the appearance of lined, wrinkled or aged skin.

In use, a small quantity of the composition, for example from 1 to 100ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, 15 it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.

Product Form and Packaging

20 The topical skin treatment compositions of the present invention may be formulated as a lotion, a cream or a gel. The composition may be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or cream may be packaged in a bottle or a 25 roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it may simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar. The composition may also be 30 included in capsules such as those described in U.S. Patent 5,063,507, incorporated herein by reference. The invention

- 11 -

accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.

5 The following specific examples further illustrate the invention, but the invention is not limited thereto. In all examples, chick pea was obtained from local supermarkets. Retinoids were obtained from Sigma. The student t-test was used to calculate all p-values.

10

EXAMPLES

The following methods were employed:

15

Methods:

1. Preparation of chick pea extracts:

20 Dried chick peas were purchased from local supermarkets and powdered in a dry grinder. An alcoholic extract of the chick peas was prepared by stirring 1 gram of the dry chick pea powder in 10 ml of ethanol for 4 to 24 hrs at room temperature. The extract was clarified by filtration and 25 centrifugation, to obtain a 10% extract of chick pea in ethanol.

2. Cell culture method:

Human adult fibroblasts obtained from sun-protected inner 30 arm of 25-30 old year female volunteers were used. Cells were grown in 1:1 DMEM/Hams F12 media containing 10% FBS, maintained at 37°C in a 5% CO₂ atmosphere under normal atmospheric oxygen tension. Third passage adult fibroblasts

were grown in DMEM media with 10% FBS in 12-well plates at a seeding density of 40,000 cells/ml/well. The cells at 80% confluence were rinsed in serum free and phenol red free (PRF) DMEM media twice. Pre-treatment with chick pea 5 extract for 4 hours was conducted and then dosed with retinoids and was incubated for 48 hours. After incubation, the wells were washed twice with 1X PBS and the cell monolayer was harvested in 100 μ l cell lysis buffer (contains 1X PBS, 1% TritonX, 0.5% sodium deoxycholate, 0.1% SDS 10 containing protease inhibitor (10mg/ml PMSF in isopropanol, 10 μ l/ml)). The suspension was spun at 14000rpm for 10 minutes, the supernatant collected and an aliquot of the supernatant used for protein quantification. The protein concentration was determined using a Pierce protein kit. The 15 remainder of the 100 μ l supernatant (cell lysate) was denatured in a mixture of 40 μ l sample buffer (NOVEX) and 0.5% Beta mercaptoethanol (BME) by boiling the sample for 5 minutes. Equal amounts of protein was then loaded onto 16% Tris-glycine gels for protein analysis by SDS page and 20 Western Immuno-blotting for CRABP-2 protein expression.

3. Detection of Cellular Retinoic Acid Binding Protein 2 (CRABP-2) in fibroblasts:

In order to measure the levels of CRABP-2 in the fibroblasts 25 prepared as described above, the cell supernatant was re-suspended in 4X sample buffer and 0.5% BME, boiled for 5 minutes and used for western blotting. Equal amounts of protein were loaded onto 16% Tris-glycine gels for CRABP-2 protein analysis by SDS page and Western Immuno-blotting. 30 The gels were transferred to nitrocellulose blots and Western Blotting was carried out using monoclonal antibodies

- 13 -

to CRABP-2 according to standard procedures. The CRABP-2 protein band was visualized in the Western Blots using the chemiluminescence system obtained from Santa Cruz Biotechnology (SantaCruz, CA). The bands in the film were 5 quantitated by densitometric scanning, the data from triplicate samples were calculated as % of control and expressed in the following tables as % increase over control (with control as 100%) +/-SD of triplicates.

10 EXAMPLES 1-4

The examples investigated the effect on CRABP-2 expression of fibroblasts of combinations of various concentrations of chick pea extract and retinoids.

15

20 EXAMPLE 1: 100 nM retinoids and 0.1 μ l of a 10% chick pea extract

Groups	CRABP-2 levels	As % of control	p value vs. control	p value vs. retinoid	p value vs. Chick pea	Synergy
Control	0.7+/- 0.2	100+/- 29	1			
Retinol	2.02+/- 0.23	289+/- 34	0.00000 56	1		
Retinyl Palmitate	1.84+/- 0.16	262+/- 24	0.00053	1		
Retinyl linoleate	2.06+/- 0.09	294+/- 12	0.00000 14	1		
Retinyl acetate	1.44+/- 0.26	206+/- 37	0.0022	1		
Chick pea ext.	1.71+/- 0.09	245+/- 13	0.00010			
Chick pea + retinol	3.38+/- 0.22	482+/- 32	4.4E-07	0.00208	0.0000 31	Yes

- 14 -

Chick pea + ret. palmitate	1.85+/- 036	264+/- 52	0.00011 3	0.975	0.564	No
Chick pea + ret. Linoleate	1.89+/- 0.19	270+/- 28	0.00007 5	0.256	0.23	No
Chick pea + ret. acetate	3.72+/- 1.06	532+/- 151	0.00001 77	0.022	0.030	Yes

EXAMPLE 2: 100 nM retinoids and 1.0 μ l of a 10% chick pea extract

5

Groups	CRABP-2 levels	As % of control	p value vs. control	p value vs. retinoid	p value vs. Chick pea	Synergy
Control	0.7+/- 0.2	100+/- 29	1			
Retinol	2.02+/- 0.23	289+/- 34	0.00000 56	1		
Retinyl Palmitate	1.84+/- 0.16	262+/- 24	0.00053	1		
Retinyl linoleate	2.06+/- 0.09	294+/- 12	0.00000 14	1		
Retinyl acetate	1.44+/- 0.26	206+/- 37	0.0022	1		
Chick pea ext.	1.46+/- 0.37	209+/- 54	0.0049			
Chick pea + retinol	5.52+/- 0.02	789+/- 3.0	7.3E-08	0.000293	7.3E-04	Yes
Chick pea + ret. palmitate	3.24+/- 0.42	462+/- 60	0.00000 19	0.049	0.016	Yes
Chick pea + ret. Linoleate	3.69+/- 1.5	527+/- 223	0.00167	0.147	0.075	No
Chick pea + ret. acetate	3.48+/- 0.21	498+/- 30	2.88E-07	0.00047	0.0012	Yes

- 15 -

EXAMPLE 3: 500 nM retinoids and 0.1 μ l of a 10% chick pea extract

5

Groups	CRABP-2 levels	As % of control	p value vs. control	p value vs. retinoid	p value vs. Chick pea	Synergy
Control	0.7+/- 0.2	100+/- 29	1			
Retinol	0.72+/- 0.04	102+/- 6	0.877	1		
Retinyl Palmitate	0.94+/- 0.31	135+/- 45	0.196	1		
Retinyl linoleate	0.81+/- 0.16	115+/- 23	0.455	1		
Retinyl acetate	1.65+/- 0.49	235+/- 70	0.0057	1		
Chick pea ext.	1.71+/- 0.09	245+/- 13	0.00010		1	
Chick pea + retinol	0.74+/- 0.22	106+/- 31	0.78	0.86	0.002 1	No
Chick pea + ret. palmitate	2.63+/- 0.58	376+/- 83	0.00001 24	0.0118	0.045	Yes
Chick pea + ret. Linoleate	3.83+/- 1.79	547+/- 256	0.00026	0.043	0.011	Yes
Chick pea + ret. acetate	6.31+/- 1.63	901+/- 233	4.5E-05	0.033	0.008 2	Yes

10

15

- 16 -

EXAMPLE 4: 500 nM retinoids and 1.0 μ l of a 10% chick pea extract:

Groups	CRABP-2 levels	As % of control	p value vs. control	P value vs. retinoid	s. hick ea	Synergy
Control	0.7+/- 0.2	100+/- 29	1			
Retinol	0.72+/- 0.04	102+/- 6	0.877	1		
Retinyl Palmitate	0.94+/- 0.31	135+/- 45	0.196	1		
Retinyl linoleate	0.81+/- 0.16	115+/- 23	0.455	1		
Retinyl acetate	1.65+/- 0.49	235+/- 70	0.0057	1		
Chick pea ext.	1.71+/- 0.09	245+/- 13	0.00010		1	
Chick pea + retinol	3.19+/- 0.14	456+/- 20	3.53E-07	9.45E-06	0.0018	Yes
Chick pea + ret. palmitate	2.78+/- 0.11	393+/- 15	1.02E-06	0.00073	0.0047	Yes
Chick pea + ret. Linoleate	3.43+/- 0.26	490+/- 37	5.7E-07	0.00013	0.0018	Yes
Chick pea + ret. acetate	3.74+/- 0.09	534+/- 13	6.27E-08	0.0044	0.0005	Yes

5

The results summarized in Examples 1-4 demonstrate that retinoids at some concentrations synergize with chick pea extract at some concentrations. Optimum synergy was observed with all the retinoids at 500 nM level and 1 μ l of chick pea extract.

- 17 -

It should be understood that the specific forms of the invention herein illustrated and described are intended to be representative only. Changes, including but not limited to those suggested in this specification, may be made in the 5 illustrated embodiments without departing from the clear teachings of the disclosure. Accordingly, reference should be made to the following appended claims in determining the full scope of the invention.

CLAIMS

1. A cosmetic skin care composition comprising:

(i) an organic solvent extract of chick pea in an amount
5 of from 0.00001 to 10 wt.%,
(ii) a retinoid selected from retinol and retinyl esters
in an amount of from 0.001 to 10 wt.%; and
(iii) a cosmetically acceptable vehicle.

10 2. A cosmetic method of improving the appearance of wrinkled,
lined, dry, flaky, aged or photodamaged skin and improving
skin thickness, elasticity, flexibility and plumpness, the
method comprising applying the composition of claim 1 to
the skin.

15

3. A cosmetic method of increasing the level of cellular
retinoic acid binding protein in the skin fibroblasts, the
method comprising applying the composition of claim 1 to
the skin.

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04304

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, CHEM ABS Data, MEDLINE, EMBASE, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 03450 A (COLETICA) 28 January 1999 (1999-01-28) the whole document ---	1-3
A, P	FR 2 779 058 A (PARFUMS CHRISTIAN DIOR) 3 December 1999 (1999-12-03) the whole document ---	1-3
A	WO 98 42303 A (UNILEVER) 1 October 1998 (1998-10-01) the whole document -----	1-3



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 January 2001

Date of mailing of the international search report

01/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fischer, J.P.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04304

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9903450	A 28-01-1999	FR 2766090	A	22-01-1999
		EP 0966268	A	29-12-1999
		JP 2000514842	T	07-11-2000
		US 5912016	A	15-06-1999
FR 2779058	A 03-12-1999	WO 9962480	A	09-12-1999
WO 9842303	A 01-10-1998	AU 725041	B	05-10-2000
		AU 6729298	A	20-10-1998
		AU 6830898	A	20-10-1998
		AU 7041798	A	20-10-1998
		BR 9808271	A	16-05-2000
		BR 9808272	A	16-05-2000
		BR 9808397	A	23-05-2000
		CN 1255847	T	07-06-2000
		CN 1257420	T	21-06-2000
		CN 1258216	T	28-06-2000
		WO 9842302	A	01-10-1998
		WO 9842304	A	01-10-1998
		EP 0971684	A	19-01-2000
		EP 0969806	A	12-01-2000
		EP 0969808	A	12-01-2000
		PL 335763	A	22-05-2000
		PL 335764	A	22-05-2000
		PL 335816	A	22-05-2000
		US 5993838	A	30-11-1999
		US 5935596	A	10-08-1999
		US 5985300	A	16-11-1999
		US 5968537	A	19-10-1999
		HU 0001514	A	28-09-2000

THIS PAGE BLANK (USPTO)